TCEAL8抗体TCEAL8兔多抗抗体Transcripti
on elongation factor S-II protein-like 8 antibody抗体TCEAL8 Antibody, Biotin conjugated抗体- ￥880 - 1320
- CUSABIO
- CN
- CSB-PA818261LD01HU
- 2025年07月15日
- ELISA
- Rabbit
- Human
企业认证
相关产品推荐更多 >
TUBA1C抗体TUBA1C兔多抗抗体alpha 1c antibody抗体TUBA1C Antibody, FITC conjugated抗体
￥880
/抗体/一抗抗体/抗体VAMP1/VAMP2/VAMP3 Antibody抗体
￥880
IFI44L抗体IFI44L兔多抗抗体GS3686Interferon-induced protein 44-like antibody抗体IFI44L Antibody抗体
￥440
SRRM1抗体SRRM1一抗抗体SRRM1_HUMAN antibody抗体SRRM1 Antibody抗体
￥3900
GLDC抗体GLDC兔多抗抗体NKH antibody抗体GLDC Antibody, Biotin conjugated抗体
￥880
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Recombinant Human Transcription elongation factor A protein-like 8 protein (1-117AA)
- 亚型：
IgG
- 形态：
Liquid
- 保存条件：
Upon receipt, store at -20℃ or -80℃. Avoid repeated freeze.
- 克隆性：
Polyclonal
- 标记物：
Biotin
- 适应物种：
Human
- 保质期：
6个月
- 抗原来源：
Homo sapiens (Human)
- 目录编号：
Q8IYN2
- 级别：
优
- 库存：
200
- 供应商：
武汉华美生物工程有限公司
- 宿主：
Rabbit
- 应用范围：
ELISA
- 浓度：
>95%,Protein G purified
- 靶点：
TCEAL8
- 抗体英文名：
TCEAL8 Antibody, Biotin conjugated
- 抗体名：
TCEAL8 antibody;Transcription elongation factor A protein-like 8 antibody;TCEA-like protein 8 antibody;Transcription elongation factor S-II protein-like 8 antibody
- 规格：
100μg/50μg
| 规格： | 100μg | 产品价格： | ￥1320.0 |
|---|---|---|---|
| 规格： | 50μg | 产品价格： | ￥880.0 |
保存缓冲液
Preservative: 0.03% Proclin 300Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
功能
May be involved in transcriptional regulation.风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Mapping Protein Distributions on Polytene Chromosomes by Immunostaining
secondary antibody. For double-labeling experiments, use fluorescence-conjugated secondary antibodies raised to the corresponding type of primary antibody. The dilution factor for each antibody needs to be determined experimentally. Blocking
cells. The catalytic domain of diphtheria toxin catalyzes the NAD+ -dependent ADP-ribosylation of the diphthamide residue in elongation factor 2, resulting in inhibition of protein synthesis (20 ,21 ). As the delivery of a single molecule
【翻译】Development trends for monoclonal antibody cancer therapeutics
has more than tripled since the 1980s, from 4.3 per year in the 1980s to 8.3 per year in the 1990s and 13.3 per year for 2000–2005. One reason for the increased investment in mAbs was the evolution of the discovery technology. The initial method for producing mAbs
技术资料暂无技术资料 索取技术资料
